NasdaqCM:LXRXPharmaceuticals
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift
Lexicon Pharmaceuticals, Inc. reported past second-quarter 2026 results showing revenue of US$692,000 versus US$28.87 million a year earlier, with net loss of US$31.78 million replacing prior net income of US$3.25 million.
This abrupt swing from profit to a wider loss, alongside sharply lower quarterly revenue, marks a clear deterioration in Lexicon’s recent operating performance.
We’ll now examine how this sharp revenue contraction and move to a wider loss may influence Lexicon’s previously...